OncoMatch/Clinical Trials/NCT07249073
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Is NCT07249073 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CAR19-BCMA dual-target CAR-T for multiple myeloma.
Treatment: CAR19-BCMA dual-target CAR-T — 1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma. 2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA overexpression (positive)
The expression of BCMA and / or CD19 in myeloma cells was positive confimed by flow cytometry or immunohistochemistry
Required: CD19 overexpression (positive)
The expression of BCMA and / or CD19 in myeloma cells was positive confimed by flow cytometry or immunohistochemistry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)
Must have received: immunomodulatory agent
have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)
Must have received: CD38 monoclonal antibody
have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)
Lab requirements
Blood counts
hgb ≥ 60g/l (transfusible)
Kidney function
creatinine ≤ 2 × uln
Liver function
total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction ≥ 50%; blood oxygen saturation >90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07249073 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory agent.
Does this trial require BCMA?
Yes, BCMA overexpression is a required biomarker for enrollment.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages